NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents
Oncogenic gene fusions are hybrid genes that result from structural DNA rearrangements, leading to deregulated activity. Fusions involving the neuregulin-1 gene (NRG1) result in ErbB-mediated pathway activation and therefore present a rational candidate for targeted treatment. The most frequently re...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
9 September 2020
|
| In: |
Annals of oncology
Year: 2020, Volume: 31, Issue: 12, Pages: 1693-1703 |
| ISSN: | 1569-8041 |
| DOI: | 10.1016/j.annonc.2020.08.2335 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.annonc.2020.08.2335 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0923753420424275 
|
| Author Notes: | J. Laskin, S.V. Liu, K. Tolba, C. Heining, R.F. Schlenk, P. Cheema, J. Cadranel, M.R. Jones, A. Drilon, A. Cseh, S. Gyorffy, F. Solca, & M. Duruisseaux |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1744287023 | ||
| 003 | DE-627 | ||
| 005 | 20220819070859.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210111s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2020.08.2335 |2 doi | |
| 035 | |a (DE-627)1744287023 | ||
| 035 | |a (DE-599)KXP1744287023 | ||
| 035 | |a (OCoLC)1341384985 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Laskin, Janessa |e VerfasserIn |0 (DE-588)1224812549 |0 (DE-627)1744288674 |4 aut | |
| 245 | 1 | 0 | |a NRG1 fusion-driven tumors |b biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents |c J. Laskin, S.V. Liu, K. Tolba, C. Heining, R.F. Schlenk, P. Cheema, J. Cadranel, M.R. Jones, A. Drilon, A. Cseh, S. Gyorffy, F. Solca, & M. Duruisseaux |
| 264 | 1 | |c 9 September 2020 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 11.01.2021 | ||
| 520 | |a Oncogenic gene fusions are hybrid genes that result from structural DNA rearrangements, leading to deregulated activity. Fusions involving the neuregulin-1 gene (NRG1) result in ErbB-mediated pathway activation and therefore present a rational candidate for targeted treatment. The most frequently reported NRG1 fusion is CD74-NRG1, which most commonly occurs in patients with invasive mucinous adenocarcinomas (IMAs) of the lung, although several other NRG1 fusion partners have been identified in patients with lung cancer, including ATP1B1, SDC4, and RBPMS. NRG1 fusions are also present in patients with other solid tumors, such as pancreatic ductal adenocarcinoma. In general, NRG1 fusions are rare across different types of cancer, with a reported incidence of <1%, with the notable exception of IMA, which represents ≈2%-10% of lung adenocarcinomas and has a reported incidence of ≈10%-30% for NRG1 fusions. A substantial proportion (≈20%) of NRG1 fusion-positive non-small-cell lung cancer cases are nonmucinous adenocarcinomas. ErbB-targeted treatments, such as afatinib, a pan-ErbB tyrosine kinase inhibitor, are potential therapeutic strategies to address unmet treatment needs in patients harboring NRG1 fusions. | ||
| 650 | 4 | |a afatinib | |
| 650 | 4 | |a ErbB-targeted treatment | |
| 650 | 4 | |a gene fusion | |
| 650 | 4 | |a invasive mucinous adenocarcinoma | |
| 650 | 4 | |a non-small-cell lung cancer | |
| 650 | 4 | |a NRG1 | |
| 700 | 1 | |a Liu, S. V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tolba, Khaled A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heining, Christoph |e VerfasserIn |0 (DE-588)1156392764 |0 (DE-627)1019233915 |0 (DE-576)502161981 |4 aut | |
| 700 | 1 | |a Schlenk, Richard Friedrich |d 1965- |e VerfasserIn |0 (DE-588)129025380 |0 (DE-627)387778004 |0 (DE-576)297454102 |4 aut | |
| 700 | 1 | |a Cheema, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cadranel, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jones, M. R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Drilon, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cseh, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gyorffy, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Solca, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Duruisseaux, M. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 31(2020), 12, Seite 1693-1703 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a NRG1 fusion-driven tumors biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents |
| 773 | 1 | 8 | |g volume:31 |g year:2020 |g number:12 |g pages:1693-1703 |g extent:11 |a NRG1 fusion-driven tumors biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.annonc.2020.08.2335 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0923753420424275 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210111 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 129025380 |a Schlenk, Richard Friedrich |m 129025380:Schlenk, Richard Friedrich |d 910000 |d 910100 |e 910000PS129025380 |e 910100PS129025380 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 999 | |a KXP-PPN1744287023 |e 383413063X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"9 September 2020","dateIssuedKey":"2020"}],"relHost":[{"part":{"volume":"31","year":"2020","text":"31(2020), 12, Seite 1693-1703","extent":"11","pages":"1693-1703","issue":"12"},"language":["eng"],"pubHistory":["1.1990 -"],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"corporate":[{"role":"isb","display":"European Society for Medical Oncology"}],"disp":"NRG1 fusion-driven tumors biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agentsAnnals of oncology","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"320428796","id":{"eki":["320428796"],"issn":["1569-8041"],"zdb":["2003498-2"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Annals of oncology","title":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology"}],"origin":[{"publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedDisp":"1990-","dateIssuedKey":"1990","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford"}]}],"id":{"eki":["1744287023"],"doi":["10.1016/j.annonc.2020.08.2335"]},"physDesc":[{"extent":"11 S."}],"title":[{"subtitle":"biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents","title":"NRG1 fusion-driven tumors","title_sort":"NRG1 fusion-driven tumors"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 11.01.2021"],"recId":"1744287023","person":[{"role":"aut","family":"Laskin","display":"Laskin, Janessa","given":"Janessa"},{"display":"Liu, S. V.","given":"S. V.","family":"Liu","role":"aut"},{"display":"Tolba, Khaled A.","given":"Khaled A.","family":"Tolba","role":"aut"},{"display":"Heining, Christoph","given":"Christoph","family":"Heining","role":"aut"},{"given":"Richard Friedrich","display":"Schlenk, Richard Friedrich","role":"aut","family":"Schlenk"},{"display":"Cheema, P.","given":"P.","role":"aut","family":"Cheema"},{"display":"Cadranel, J.","given":"J.","family":"Cadranel","role":"aut"},{"given":"M. R.","display":"Jones, M. R.","family":"Jones","role":"aut"},{"role":"aut","family":"Drilon","given":"A.","display":"Drilon, A."},{"role":"aut","family":"Cseh","given":"A.","display":"Cseh, A."},{"display":"Gyorffy, S.","given":"S.","role":"aut","family":"Gyorffy"},{"display":"Solca, F.","given":"F.","family":"Solca","role":"aut"},{"given":"M.","display":"Duruisseaux, M.","role":"aut","family":"Duruisseaux"}],"name":{"displayForm":["J. Laskin, S.V. Liu, K. Tolba, C. Heining, R.F. Schlenk, P. Cheema, J. Cadranel, M.R. Jones, A. Drilon, A. Cseh, S. Gyorffy, F. Solca, & M. Duruisseaux"]},"language":["eng"]} | ||
| SRT | |a LASKINJANENRG1FUSION9202 | ||